Preferences
Related Series
Related Segments
Drug Diversion Monitoring 2023
New Advanced Capabilities Beginning to Show Promise
Drug diversion monitoring is a key area that helps healthcare organizations improve patient safety and prevent drug waste and misuse. The second generation of drug diversion monitoring solutions utilizes predictive models, artificial intelligence (AI), and machine learning (ML), and users are beginning to see outcomes such as correctly identified risks, reduced false positives, and increased efficiency. This report examines which vendors are driving outcomes, how advanced AI/ML capabilities are impacting the user experience, and how well vendors partner with and support customers.
If you don't have a login, getting started is easy.
Key Findings:
- Bluesight & Protenus Customers Want Continued Development for Advanced Capabilities; Invistics’ Smaller Customer Base Seeing Success with AI
- Invistics & HelioMetrics Performing Well Despite Limited Market Adoption; Imprivata Customers Report Continued Struggles Post-Acquisition
- Despite Advancing Integration, BD Customers Continue to Experience Functionality Challenges
- Protenus Leads in Supporting Customers and Keeping Promises; Bluesight Customers Feel Support Is Declining as Vendor Grows
Writer
Natalie Hopkins
Designer
Jessica Bonnett
Project Manager
Andrew Wright
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.